Abstract
Among the global health challenges, diabetes mellitus—an archetypal meta-bolic disorder—continues to increase in prevalence. According to the World Health Organization, the number of diagnosed patients has more than tripled over the past two decades, making it a significant cause of disability and death. The accelerated ageing of the population, the prevalence of sedentary behaviours, and the problem of over-nutrition are all contributing to the increase in the prevalence of diabetes mellitus. Although conventional interventions such as glucose-lowering medications, dietary modification, and physical exercise can alleviate symptoms, they are unable to overcome the inherent limitations of fluctuating efficacy and poor patient compliance. Modern medicine is undergoing a therapeutic paradigm shift: breakthroughs in genomics technology have made individualised medication possible, artificial intelligence-assisted diagnostic systems have dramatically improved the accuracy of disease typing, and real-time monitoring by wearable devices has provided data support for dynamic adjustments to treatment regimens. By integrating multi-omics data (including genomic features, metabolomic profiles, and the composition of intestinal flora) with patients' behavioural patterns, clinicians are able to build precise treatment models and achieve the transformation from “one person for every patient” to “tailor-made”. This individualised strategy, based on big data, not only optimises glycemic control but also significantly reduces the risk of long-term complications such as retinopathy and nephropathy. In this study, we focus on the cutting-edge advances in precision medicine for diabetes, and systematically discuss the key issues of biomarker screening, development of intelligent diagnostic and treatment systems, and optimisation of personalised intervention plans, with the aim of providing theoretical basis and practical guidance for the construction of the next-generation diabetes management system, and ultimately realising the leap-forward development from disease treatment to health management.
References
[1] Yao Y, Li W, Gao J, et al. Research progress of diabetic foot ulcers complicated by diabetes mellitus combined with tuberculosis. Chin J Anti-Tuberc. 2024;46(S2):517-9.
[2] Ren P. Current status and progress of research on integrated management of hypertension and diabetes mellitus. Front Med. 2024;14(33):55-8.
[3] Zhang N, Gao L, Chen Z, et al. Progress of optical coherence tomography imaging in the treatment of diabetic macular oedema with anti-vascular endothelial growth factor drugs. Chin Med J. 2024;21(32):74-6+86. doi:10.20047/j.issn1673-7210.2024.32.13.
[4] Jiang M, Wang Y, He S, et al. Progress in the pathogenesis and treatment of diabetic dry eye. New Prog Ophthalmol. 2024;44(11):914-9. doi:10.13389/j.cnki.rao.2024.0173.
[5] Gao S, Xiong Y, Tang C, et al. Research progress of nano drug delivery system in the treatment of diabetic nephropathy. Adv Physiol Sci. 2024;55(6):575-83. doi:10.20059/j.cnki.pps.2024.10.1175.
[6] Cui L, Lin L, Zhang Y, et al. Research progress of drug-coated balloon for the treatment of coronary artery lesions combined with diabetes mellitus. J Clin Cardiol. 2024;40(10):853-8. doi:10.13201/j.issn.1001-1439.2024.10.014.
[7] Song D, Jiang S, Guo M, et al. Research progress of pharmacological treatment of diabetic nephropathy. Jilin Med Sci. 2024;45(9):2215-8.
[8] Jiang S, Yan L, Wang S, et al. Chinese expert consensus on prostaglandin analogues for the treatment of chronic kidney disease in patients with type 2 diabetes mellitus. Chin J Pract Diagn Ther. 2024;38(9):865-70.
doi:10.13507/j.issn.1674-3474.2024.09.001.
[9] Wang J, Xue X, Xia B, et al. Progress of pharmacological treatment of diabetic foot. Diabetes New World. 2023;26(1):195-8. doi:10.16658/j.cnki.1672-4062.2023.01.195.
[10] Liu J. Research on the current status and progress of diabetes mellitus pharmacological treatment. Med Inf. 2022;35(9):69-72.
How to cite this paper
Recent Advances in Diabetes Drug Therapy and Personalized Treatment Strategies
How to cite this paper: Zijuan Wen, Qing Li. (2025) Recent Advances in Diabetes Drug Therapy and Personalized Treatment Strategies. International Journal of Clinical and Experimental Medicine Research, 9(2), 221-225.
DOI: http://dx.doi.org/10.26855/ijcemr.2025.03.010